Novo Nordisk and Vivani Medical's Weight Management Strategy

In July 2026, Novo Nordisk evaluated Vivani's semaglutide implant as a potential obesity and diabetes treatment, with aims to simplify long-term weight management. The British Nutrition Foundation further stated that weight management relies on energy intake, energy use, daily activities, and medication. For people struggling with weight loss management due to diabetes, semaglutide (like GLP-1) can help regulate insulin, reduce appetite, and also manage blood sugars. Novo Nordisk and Vivani Medical have agreed to evaluate the company’s semaglutide drug implant, NPM-139.

The NPM-139 utilizes Vivani’s NanoPortal platform technology to assist in the development of chronic weight management. Vivani is expecting to initiate a Phase 1, which is a randomized and first-in-human study to evaluate the NPM-139 implant with injections. The study aims to analyze the drug’s tolerability and safety in NPM-139.

The company made use of the NanoPortal, which is an implant platform that is designed to provide a near-constant, controlled release of medication over an extended period, thus helping patients receive a consistent dose while reducing the fluctuations associated with traditional drug delivery methods. Its innovative nanopore technology can be tailored to the size of specific drug molecules, where pores are just large enough to enable steady, long-term drug release. The device features a simple and space-efficient design with no pumps or electronics, allowing for easy subdermal insertion and removal while simultaneously maximizing drug capacity. 

Impact on the Healthcare Industry 

The impact of weight management on the healthcare industry is quite significant, as it is reshaping preventive care, treatment, and long-term support. Healthcare organizations all over the world are reevaluating their approach towards prevention and treatment, recognizing weight management as a chronic health issue. This market shift is further being driven by the increasing financial pressure from healthcare systems, productivity loss from employers, and long-term sustainability challenges from public health programs. Modern healthcare models are seen to emphasize sustainable, individualized care that can go beyond basic lifestyle counseling. This also includes the integration of technology, such as digital health platforms and remote monitoring.

As the healthcare sector has advanced, the range of medical tools and drugs available to support weight management has also increased. Healthcare professionals now consider a variety of options depending on patient needs, including nutritional counseling, injections, and sometimes even surgical intervention. Various weight loss medications are often utilized as part of a broader treatment plan, particularly when patients have not achieved results through lifestyle changes alone or when comorbidities exist.

Impact on the Weight Loss Services Market

The global weight loss services market size accounted for USD 20.97 billion in 2025 and is predicted to increase from USD 22.74 billion in 2026 to approximately USD 46.05 billion by 2035, expanding at a CAGR of 8.18% from 2026 to 2035.

According to Precedence Research, weight loss management helps reduce the overall body weight and manage it in the ideal state. These services help to decrease weight through various processes like changing the consumer's diet, increasing physical activities, medication, surgeries, and others. The overall aim of weight loss services is to manage overweight and obesity and reduce the risk of chronic diseases. The rising number of obese people globally, who are more likely to be prone to chronic illnesses like diabetes, high blood pressure, and cardiovascular disorders, is driving the demand for weight loss services, which in turn fosters innovation for weight management drugs.

Impact on the Prescription Weight Loss Medications Market

The global prescription weight loss medications market size accounted for USD 12.38 billion in 2025 and is predicted to increase from USD 13.93 billion in 2026 to approximately USD 40.30 billion by 2035, expanding at a CAGR of 12.53% from 2026 to 2035.

According to Precedence Research, the weight loss medications market includes pharmacological treatments that are specifically approved or widely prescribed for long-term overweight and obesity management. These medications work in terms of appetite suppression, metabolic modulation, nutrient absorption alteration, or incretin pathways in order to support sustained weight loss in patients with elevated BMI and associated comorbidities. The market includes GLP-1 receptor agonists, combination therapies, SGLT2 inhibitors, and emerging molecular classes.

The introduction of GLP-1 agonists such as Tirzepatide, Mounjaro, Semaglutide, and Wegovy is helping in expanding treatment efficacy and boosting patient access, thus boosting market awareness as well as expansion. The surge in clinical trials for newer and more potent oral and injectable drugs is anticipated to fuel the market's expansion during the forecast period.

About Novo Nordisk

Novo Nordisk is a global pharmaceutical company that is headquartered in Denmark and is dedicated to driving change to defeat chronic diseases. The company’s main aim is to innovate in diabetes care, obesity treatment, and other serious conditions like rare blood and endocrine disorders, cardiovascular diseases, and emerging areas. Operating in 80 countries with research and development in 5 countries and manufacturing in 13, Novo Nordisk is making significant strides in the biopharmaceutical industry.

Novo Nordisk stands as a beacon in the global pharmaceutical industry as it is well-renowned for its innovative solutions in diabetes treatment, obesity management, rare diseases, and emerging areas like cardiovascular therapies.